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Mitochondrial disorders (MDs) are caused by impairment 
of the mitochondrial electron transport chain (ETC). The ETC 
is needed for oxidative phosphorylation, which provides the cell 
with the most efficient energy outcome in terms of ATP produc-
tion. One of the pathogenic mechanisms of MDs is the genera-
tion of reactive oxygen species.
Potential  pharmacological  approaches  for  MDs  include 
ETC  cofactors  (i.e.,  Coenzyme  Q10)  and  other  metabolites 
(i.e., carnitine), antioxidants, neuroprotective drugs (i.e., tetra-
cyclines), bezafibrate (an activator of PGC-1alpha). Controlled 
trials in large cohorts of patients are still needed, because ther-
apy for mitochondrial diseases remains inadequate and mostly 
symptomatic. It will be important to develop a better under-
standing of the role of oxidative stress, since it may lead to the 
development of more effective treatment strategies.
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Although Duchenne Muscular Dystrophy (DMD) has been 
described 175 years ago, therapies for DMD remain supportive 
rather than curative. Gene- and cell-based therapies designed 
to  replace  the  missing  gene  and/or  dystrophin  protein  have 
achieved varying and controversial degrees of success. Three 
different  therapeutic  approaches  are  currently  under  study: 
1. Gene therapy; 2. Cellular therapy; 3. Pharmacological ther-
apy. The latter will be examined into the three fundamental as-
pects: 1. Utrophin over-expression; 2. Dystrophin re-expression; 
3. Reversal of dystrophic phenotype.
1.  Utrophin  over-expression.  Recent  developments  in  un-
derstanding the regulatory pathways that govern utrophin 
expression,  stimulated  studies  using  activators  of  these 
pathways to alleviate the dystrophic symptoms in DMD 
animal models. Drugs used to this aim are: Interleukin 6, 
Agrin, Heregulin, Calcineurin. All these drugs are able to 
induce overexpression of the sarcolemmal utrophin in vitro 
and in neonatal mdx skeletal muscles. The results of these 
preclinical studies are promising and stimulate to imple-
ment appropriate utrophin-based drug therapies for DMD 
patients.
2.  Dystrophin re-expression can be achieved by drug ther-
apy  –  aminoglycosides,  antisense  strategy  and  chimera-
plasty – or by cell therapy – myoblasts and stem cells – or 
by  gene  therapy. Aminoglycosides  have  been  proven  to 
cause an extensive misreading of the RNA code, allowing 
the insertion of alternative amino acids at the site of the 
mutated codon. Although it is now considered a therapeutic 
strategy for DMD caused by point-mutations, unfortunate-
ly it is applicable to only 1% of DMD patients.
3.  Reversal of dystrophic phenotype can be achieved by the 
use of corticosteroids. The two main classes of steroids 
used are prednisone or prednisolone and deflazacort (DFZ). 
They are probably equally effective in stabilizing muscle 
strength but may have different side-effect profiles. The ex-
act mechanism by which steroids slow the dystrophic proc-
ess is yet under investigation. Corticosteroids have been 
found to stabilize or improve muscle strength in boys with 
DMD and to have beneficial effects on the different aspects 
of DMD, such as walking time prolongation, development 
of scoliosis, development of respiratory insufficiency and 
development of cardiac involvement. A systematic review 
of the Cochrane database and the personal experience on 
more  than  200  DMD  patients  treated  with  DFZ  for  20 
years, let us to conclude that long term steroid therapy is 
able to prolong ambulation by 2 to 5 years, reduce the need 
for spinal stabilization surgery, improve cardiopulmonary 
function, delay the need for non invasive nasal ventilation 
and finally increase survival and quality of life of patients 
with Duchenne muscular dystrophy.
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The most common autoimmune inflammatory myopathies 
include Polymyositis (PM), Dermatomyositis (DM), Necrotiz-
ing Autoimmune Myositis (NAM) and Inclusion Body Myositis 
(IBM). Polymyositis still remains an uncommon but frequently 
misdiagnosed disorder. NAM, IBM, and inflammatory dystro-
phies are the myopathies most often misdiagnosed as PM. The 
presence of MHC-1/CD8 complex remains the most useful im-
munopathologic marker because it reliably distinguishes, most 
of the times, the antigen-driven inflammatory cells that charac-
terize PM and IBM from the non-specific, secondary inflam-
mation seen in dystrophies, and from the non-MHC-I, macro-
phage-mediated process, seen in NAM. In PM and IBM, the 
co-stimulatory molecules ICOS/ICOS-L and PD-L1 are strong-
ly upregulated, indicating an immunological synapse formation 
between cytotoxic T cells and muscle fibers.
In s-IBM, the inflammatory cells invade non-vacuolated 
fibers while the vacuolated fibers are not invaded by T cells im-
plying two independent processes: a primary immune process 
with antigen driven T cells identical to PM, and a degenerative 
process in which β-amyloid and related proteins may participate 
in vacuolar degeneration. An interrelationship between inflam-
mation and amyloid-related or stressor proteins is the most ex-
citing new observation with potential therapeutic implications.
DM is a complement-mediated microangiopathy affecting 
skin and muscles; the role of alpha-interferon-related molecules 
seem to be secondary events. NAM is a histologically distinct 
myopathy of acute/subacute onset that can be associated with 
cancer, viral infections, autoimmunity, or statins. Whether cer-